India Ulcerative Colitis Drug Market Size, Trend and Research Report 2022: Radiant Insights, Inc

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

It is worth noting that in India, the local drug companies produce their own biosimilars, without many regulatory guidelines or any regard for the patent protection of the marketed products.

For more information kindly visit: http://www.radiantinsights.com/research/pharmapoint-ulcerative-colitis-india-drug-forecast-and-market-analysis-to-2022

For the treatment of UC, Indian physicians rely heavily on non-pharmacological methods, such as dietary recommendations, and for pharmacologic therapy, they use generic products within the corticosteroids and 5-ASA classes. GlobalData’s physician survey showed that these drugs are the mainstay of treatment for mild to moderate UC in India, as well as at earlier lines of therapy for severe disease.

Scope

– Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

– Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.

– Sales forecast for the top drugs in India from 2012-2022.

– Analysis of the impact of key events as well the drivers and restraints affecting the India Ulcerative Colitis market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return

– Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.

– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

– Make more informed business decisions from insightful and in-depth analysis of drug performance

– Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

About Us

 

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For more information visit: Radiant Insights

Contact:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Blog URL: http://www.esorics2010.org/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s